Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rinn

Showing results (371-380 of 443) with videos related to

Pageof 45
Sort By:
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
Dietary plant diversity predicts early life microbiome maturationTeresa K McDonald, Ammara Aqeel, Ben Neubert, et al.
Cell Genomics|January 3, 2024
Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responsesErica Normandin, Sergio Triana, Siddharth S Raju, et al.
Nature Genetics|November 24, 2020
Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traitsAvik Choudhuri, Eirini Trompouki, Brian J Abraham, et al.
Nature|December 15, 2015
The histone chaperone CAF-1 safeguards somatic cell identitySihem Cheloufi, Ulrich Elling, Barbara Hopfgartner, et al.
Open Forum Infectious Diseases|April 23, 2025
Oral Swab Testing With Xpert MTB/RIF Ultra for the Diagnosis of Tuberculosis in Children Aged <5 Years in Uganda: An Exploratory Interim Analysis of Diagnostic Accuracy in the NOD-pedFEND CohortNisreen Khambati, Kanyange Angel Moureen, Francesca Wanda Basile, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
BMC Genomics|December 24, 2014
Simultaneous analysis of large-scale RNAi screens for pathogen entryPauli Rämö, Anna Drewek, Cécile Arrieumerlou, et al.
Annals of the New York Academy of Sciences|November 18, 2021
Noncoding RNAs: biology and applications-a Keystone Symposia reportJennifer Cable, Edith Heard, Tetsuro Hirose, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Pageof 45

Showing results (371-380 of 443) with videos related to

Sort By:
Pageof 45
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
Dietary plant diversity predicts early life microbiome maturationTeresa K McDonald, Ammara Aqeel, Ben Neubert, et al.
Cell Genomics|January 3, 2024
Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responsesErica Normandin, Sergio Triana, Siddharth S Raju, et al.
Nature Genetics|November 24, 2020
Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traitsAvik Choudhuri, Eirini Trompouki, Brian J Abraham, et al.
Nature|December 15, 2015
The histone chaperone CAF-1 safeguards somatic cell identitySihem Cheloufi, Ulrich Elling, Barbara Hopfgartner, et al.
Open Forum Infectious Diseases|April 23, 2025
Oral Swab Testing With Xpert MTB/RIF Ultra for the Diagnosis of Tuberculosis in Children Aged <5 Years in Uganda: An Exploratory Interim Analysis of Diagnostic Accuracy in the NOD-pedFEND CohortNisreen Khambati, Kanyange Angel Moureen, Francesca Wanda Basile, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
BMC Genomics|December 24, 2014
Simultaneous analysis of large-scale RNAi screens for pathogen entryPauli Rämö, Anna Drewek, Cécile Arrieumerlou, et al.
Annals of the New York Academy of Sciences|November 18, 2021
Noncoding RNAs: biology and applications-a Keystone Symposia reportJennifer Cable, Edith Heard, Tetsuro Hirose, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Pageof 45